WO2010142660A3 - Système d'administration de médicaments - Google Patents
Système d'administration de médicaments Download PDFInfo
- Publication number
- WO2010142660A3 WO2010142660A3 PCT/EP2010/057965 EP2010057965W WO2010142660A3 WO 2010142660 A3 WO2010142660 A3 WO 2010142660A3 EP 2010057965 W EP2010057965 W EP 2010057965W WO 2010142660 A3 WO2010142660 A3 WO 2010142660A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sirna
- microparticles
- useful
- formulations
- lung
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Abstract
La présente invention concerne des formulations pharmaceutiquement actives constituée, d'une part de microparticules d'ARN interférent court de dimensions définies, d'autre part d'un polymère biodégradable hautement hydrophobe, et enfin d'un lipide cationique servant à la fois d'émulsifiant amphipathique et d'entité de liaison à l'ARN interférent court. L'invention concerne également des procédés de fabrication de ces microparticules. Ces formulations de microparticules, qui sont particulièrement adaptées à l'administration pulmonaire d'ARN interférent court, sont indiquées dans le cas d'un traitement d'affections pulmonaires.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09162257.1 | 2009-06-09 | ||
EP09162257 | 2009-06-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010142660A2 WO2010142660A2 (fr) | 2010-12-16 |
WO2010142660A3 true WO2010142660A3 (fr) | 2011-08-25 |
Family
ID=41217671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/057965 WO2010142660A2 (fr) | 2009-06-09 | 2010-06-08 | Système d'administration de médicaments |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010142660A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013006837A1 (fr) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Emulsions huile dans eau cationiques |
CN102389756B (zh) * | 2011-08-11 | 2014-01-01 | 长春金赛药业有限责任公司 | 复乳法制备微球的方法 |
DE102011114986A1 (de) * | 2011-09-28 | 2013-03-28 | Ethris Gmbh | Sprühsystem |
DE102017100317A1 (de) | 2017-01-10 | 2018-07-12 | Friedrich-Schiller-Universität Jena | Nanostrukturiertes Trägersystem zum Gentransport |
IT202100032393A1 (it) * | 2021-12-23 | 2023-06-23 | Torino Politecnico | Metodo per la preparazione di nanoparticelle polimeriche ibride per il rilascio di farmaci oligonucleotidici nelle terapie farmacologiche a scopo rigenerativo, curativo e preventivo |
WO2023172747A1 (fr) * | 2022-03-11 | 2023-09-14 | W. L. Gore & Associates, Inc. | Particules bioabsorbables et procédé d'utilisation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003015816A1 (fr) * | 2001-08-10 | 2003-02-27 | Dynavax Technologies Corporation | Preparations d'oligonucleotides immunomodulateurs et leurs procedes d'utilisation |
WO2004026453A2 (fr) * | 2002-09-06 | 2004-04-01 | Genteric, Inc. | Microcapsules et procedes d'utilisation associes |
-
2010
- 2010-06-08 WO PCT/EP2010/057965 patent/WO2010142660A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003015816A1 (fr) * | 2001-08-10 | 2003-02-27 | Dynavax Technologies Corporation | Preparations d'oligonucleotides immunomodulateurs et leurs procedes d'utilisation |
WO2004026453A2 (fr) * | 2002-09-06 | 2004-04-01 | Genteric, Inc. | Microcapsules et procedes d'utilisation associes |
Non-Patent Citations (2)
Title |
---|
TAHARA KOHEI ET AL: "[Development of gene delivery system using PLGA nanospheres]", YAKUGAKU ZASSHI : JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN OCT 2007, vol. 127, no. 10, October 2007 (2007-10-01), pages 1541 - 1548, XP002553274, ISSN: 0031-6903 * |
TAKASHIMA ET AL: "Spray-drying preparation of microparticles containing cationic PLGA nanospheres as gene carriers for avoiding aggregation of nanospheres", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 343, no. 1-2, 30 August 2007 (2007-08-30), pages 262 - 269, XP022223274, ISSN: 0378-5173 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010142660A2 (fr) | 2010-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010008582A3 (fr) | Système permettant d'administrer un médicament aux cellules phagocytaires | |
WO2010142660A3 (fr) | Système d'administration de médicaments | |
WO2011153493A3 (fr) | Lipides biodégradables pour l'administration de principes actifs | |
WO2009129387A3 (fr) | Lipides cationiques et utilisations associees | |
EP2007398A4 (fr) | Vitesses d'administration élevées pour préparations médicamenteuses lipidiques et méthodes de traitement associées | |
WO2011022460A8 (fr) | Nouveaux lipides cationiques avec différents groupes de tête pour délivrance d'oligonucléotide | |
WO2012042224A8 (fr) | Composition pharmaceutique | |
WO2011043913A3 (fr) | Nouveaux lipides cationiques à chaînes lipidiques courtes pour une administration d'oligonucléotides | |
NZ603386A (en) | Pharmaceutical compositions and administrations thereof | |
WO2012003377A3 (fr) | Procédé de préparation de tissu chorial et produits dérivés dudit tissu | |
WO2013052167A3 (fr) | Nanoparticules encapsulées dans une membrane et leur procédé d'utilisation | |
WO2013105101A8 (fr) | Nanoparticules lipidiques solides encapsulant un médicament hydrophile/amphiphile et leur procédé de préparation | |
WO2012103038A3 (fr) | Compositions de nanoparticules, leurs formulations et leurs utilisations | |
WO2009012303A3 (fr) | Nanoparticules thérapeutiques stables | |
WO2011053982A3 (fr) | Compositions thérapeutiques à base de nucléases et méthodes | |
WO2009117130A3 (fr) | Formulation à libération prolongée contenant une cire | |
WO2008115469A3 (fr) | Rôle de la signalisation par hérisson dans l'athérosclérose et les maladies cardiovasculaires | |
WO2009138473A3 (fr) | Libération intracellulaire d'anticorps | |
WO2012050922A3 (fr) | Formes pharmaceutiques à rétention gastrique pour la libération prolongée d'acamprosate dans le tractus gastro-intestinal supérieur | |
WO2010021607A3 (fr) | Préparation pharmaceutique | |
WO2010131907A3 (fr) | MODE D'ADMINISTRATION D'ARNic AU MOYEN DE NANOPARTICULES POLYMÈRES AUTO-ASSEMBLÉES | |
WO2010143969A3 (fr) | Particules d'administration de médicament présentant une sensibilité acoustique comprenant de la phosphatidyléthanolamine formant des structures non lamellaires | |
WO2011163651A3 (fr) | Procédés et compositions pour l'administration au snc de ss-galactocérébrosidase | |
WO2009053885A3 (fr) | Procédés de préparation de microparticules de polymère | |
WO2012162439A3 (fr) | Compositions comprenant de l'acide fusidique et leurs emballages |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10724811 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10724811 Country of ref document: EP Kind code of ref document: A2 |